Valuation: Amplia Therapeutics Limited

Market Cap 5.65Cr 3.94Cr 3.51Cr 3.27Cr 2.98Cr 5.6Cr 378.97Cr 40Cr 15Cr 193.42Cr 15Cr 14Cr 621.73Cr P/E 2027 *
-4.78x
P/E 2028 * -15.7x
Enterprise Value 3.86Cr 2.69Cr 2.4Cr 2.23Cr 2.03Cr 3.83Cr 258.83Cr 27Cr 11Cr 132.11Cr 10Cr 9.87Cr 424.63Cr EV / Sales 2027 *
-
EV / Sales 2028 * 3.48x
Free-Float
90.48%
Yield 2027 *
-
Yield 2028 * -
1 day+4.55%
1 month-11.54%
3 months-25.81%
6 months-23.33%
Current year-23.33%
1 week 0.11
Extreme 0.11
0.12
1 month 0.11
Extreme 0.11
0.14
Current year 0.1
Extreme 0.1
0.28
1 year 0.1
Extreme 0.1
0.28
3 years 0.05
Extreme 0.049
0.42
5 years 0.05
Extreme 0.049
0.42
10 years 0.04
Extreme 0.045
18.3
Manager TitleAgeSince
Chief Executive Officer - 05/12/2022
Director of Finance/CFO - 01/10/2021
Chief Tech/Sci/R&D Officer - 12/05/2025
Director TitleAgeSince
Director/Board Member 70 02/09/2015
Chairman - 25/05/2018
Chairman - 30/06/2026
Date Insider Type Main position Quantity % Market Cap. Importance
08/09/25 Exercice

Chairman

7,50,000 0.1933%
08/09/25 Free

Founder

4,47,000 0.1152%
08/09/25 Exercice

Director

5,35,000 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
+4.55%0.00%-34.29%+30.68% 3.94Cr
+4.16%+3.42%+49.37%+94.17% 7.43TCr
+1.70%-2.45%+21.74%+76.99% 5.7TCr
+2.57%+0.79%+5.64%+37.20% 4.83TCr
+0.50%+2.94%+344.62%+722.17% 4.45TCr
+3.05%-1.80%+28.78%+34.51% 4.38TCr
+1.00%-1.46%+5.17%+111.90% 4.11TCr
-0.54%+2.41%+9.31%+58.85% 3.11TCr
+4.51%+8.22%+37.86%+32.49% 2.9TCr
+0.76%-1.45%-7.44%-11.12% 2.45TCr
Average +2.24%-0.97%+46.08%+118.79% 3.94TCr
Weighted average by Cap. +2.21%-0.46%+58.93%+137.03%

Financials

2027 *2028 *
Net sales - 95L 66.21L 59.06L 55.03L 50.08L 94.3L 64Cr 6.65Cr 2.59Cr 33Cr 2.49Cr 2.43Cr 104.6Cr
Net income -1.16Cr -80.84L -72.12L -67.19L -61.14L -1.15Cr -78Cr -8.12Cr -3.16Cr -40Cr -3.03Cr -2.97Cr -127.73Cr -41L -28.57L -25.49L -23.75L -21.61L -40.7L -28Cr -2.87Cr -1.12Cr -14Cr -1.07Cr -1.05Cr -45Cr
Net Debt -1.79Cr -1.25Cr -1.11Cr -1.04Cr -94.35L -1.78Cr -120.14Cr -13Cr -4.87Cr -61Cr -4.68Cr -4.58Cr -197.1Cr -2.34Cr -1.63Cr -1.45Cr -1.36Cr -1.23Cr -2.32Cr -157.06Cr -16Cr -6.37Cr -80Cr -6.12Cr -5.99Cr -257.66Cr
Logo Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Employees
-
Date Price Change Volume
06/26/06 A$0.1150 +4.55% 92,240
05/26/05 A$0.1100 0.00% 28,310
02/26/02 A$0.1100 -4.35% 3,91,711
01/26/01 A$0.1150 0.00% 4,78,314
30/26/30 A$0.1150 0.00% 363
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1100AUD
Average target price
0.4200AUD
Spread / Average Target
+281.82%

Quarterly revenue - Rate of surprise